FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure
East Hanover, N.J., Oct. 1, 2019– Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 1, 2019 Category: Drugs & Pharmacology Source Type: news
CVS Pulls Zantac And Similar Heartburn Drugs Over Cancer Concerns
(CNN) — CVS Pharmacy has stopped selling Zantac, as well as its generic version of the heartburn medication, over concerns that they might contain a substance that could cause cancer.
CVS, the largest pharmacy chain in the country, said over the weekend it was suspending sale of Zantac and other products which contain ranitidine until further notice. The US Food and Drug Administration said earlier this month that it has learned that some ranitidine — acid-reducing and heartburn medicines, including those known by the brand name Zantac — contain low levels of an impurity that could cause cancer.
Zantac an...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 30, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Featured Health News Syndicated CBSN Boston CVS Zantac Source Type: news
Rosemarie Riddell Bogdan, Esq. Appointed to Plaintiffs ’ Steering...
Martin, Harding & Mazzotti, LLP Partner Rosemarie Riddell Bogdan appointed to a leadership position on the Plaintiffs’ Personal Injury Steering Committee in National Valsartan NDMA contamination...(PRWeb September 25, 2019)Read the full story at https://www.prweb.com/releases/rosemarie_riddell_bogdan_esq_appointed_to_plaintiffs_steering_committee_in_national_valsartan_ndma_products_liability_litigation/prweb16596119.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2019 Category: Pharmaceuticals Source Type: news
FDA Expands Recall Of Blood Pressure Drugs Again
(CNN) — Torrent Pharmaceuticals Ltd. has expanded its voluntary recall of two blood pressure medications after trace amounts of a potentially cancer-causing impurity were found during testing.
The recall affects Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets.
Tests of some of those medications revealed amounts of N-methylnitrosobutyric acid (NMBA) that were above the US Food and Drug Administration’s daily acceptable levels.
This recall is related to the valsartan recall that has been expanded multiple times since July, when separate lots of blood pressure medications from dif...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Recall Valsartan Source Type: news
Novartis Stops Distributing Generic Zantac Over Potential Cancer-Causing Ingredient
WASHINGTON (CBS) – Drug maker Novartis has halted distribution of generic versions of Zantac. The popular heartburn medication has been investigated for containing a potential cancer-causing ingredient.
A Novartis spokesman told CBS News “our internal investigation is ongoing to determine further details,” and the drug can remain on pharmacy shelves for now. Sanofi, the French pharmaceutical company that makes Zantac, said it had no plans to stop distribution or production.
Last week, the FDA said that ranitidine treatments like Zantac have been found to contain a “probable” carcinogenic impurity known as N-nitro...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Syndicated CBSN Boston FDA Zantac Source Type: news
Questions raised over quality of trials supporting new cancer drugs approvals
Potential risk of bias in half of trials supporting new cancer drug approvals in Europe, study suggests Related items fromOnMedica Only half of new cancer drugs extend or improve life Drugs regulators “put profits before patients” Doctors debate long-term use of psychiatric drugs Withdrawn valsartan meds not linked to short-term cancer risk We must revise drug regulatory framework at EU and national levels (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 18, 2019 Category: UK Health Source Type: news
Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU
Some patients in cardiogenic shock may transition from IV vasoactive agents to sacubitril/valsartan without going hypotensive, suggests a small case series; PA-pressure guidance was crucial.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 17, 2019 Category: Intensive Care Tags: Cardiology News Source Type: news
PARAGON-HF: Is There a Role for the ARNI in HFpEF? PARAGON-HF: Is There a Role for the ARNI in HFpEF?
Ileana Pi ñ a quizzes investigator Burkert Pieske on the findings for sacubitril/valsartan in patients with HFpEF, including exploratory subgroup analyses and use of mineralocorticoid-receptor antagonists.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 16, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Zantac Has Low Levels of a Cancer-Causing Chemical, the F.D.A. Says
The chemical, NDMA, is the same one found in the blood pressure drug valsartan, which led to widespread recalls last year. (Source: NYT)
Source: NYT - September 13, 2019 Category: American Health Authors: Katie Thomas and Sheila Kaplan Tags: Drugs (Pharmaceuticals) Heartburn Product Tests Food and Drug Administration European Medicines Agency carcinogen Zantac your-feed-healthcare Source Type: news
FDA Finds Low Levels Of Cancer-Linked Impurity In Common Heartburn Drugs
(CNN) — The US Food and Drug Administration said on Friday that it has learned that some ranitidine — acid-reducing and heartburn medicines, including those known by the brand name Zantac — contain low levels of an impurity that could cause cancer.
The nitrosamine impurity known as N-nitrosodimethylamine or NDMA has been classified as a probable human carcinogen based on lab tests, and this isn’t the first time that it has been detected in a common medication.
Since last year, the FDA has been investigating NDMA and other impurities in blood pressure and heart failure medicines known as angiotensin ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 13, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN FDA Heartburn Source Type: news
Cardiac'Shrinkage' on Sacubitril/Valsartan May Rival CRT in HF Cardiac'Shrinkage' on Sacubitril/Valsartan May Rival CRT in HF
LV volumes fell and LVEF rose, often 10 points or more, after a year on the ARNI. That approaches gains on cardiac resynchronization therapy,"the reverse-remodeling champion," a researcher notes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 11, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Sacubitril-Valsartan Does Not Impact Aortic Stiffness in HFrEF
WEDNESDAY, Sept. 4, 2019 -- For patients with heart failure and reduced ejection fraction (HFrEF), sacubitril-valsartan does not impact aortic stiffness versus enalapril but is associated with improvements in cardiac structure and function,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2019 Category: Pharmaceuticals Source Type: news
PARAGON-HF: Sacubitril/Valsartan Frustrates in Preserved-EF HF PARAGON-HF: Sacubitril/Valsartan Frustrates in Preserved-EF HF
Hopes were the trial would provide something new: solid clinical trial backing for an HFpEF drug therapy. It didn ' t, but some say it supports consideration of the drug in at least one HFpEF subgroup.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
HRT users told to discuss breast cancer risk with GP
MHRA says discussion should take place at next GP appointment after study shows persistent raised risk of breast cancer after HRT use Related items fromOnMedica Breast cancer rate falls with decline in HRT use New breast cancer drug ‘unaffordable’ for NHS NICE rejects breast cancer drug for NHS funding Withdrawn valsartan meds not linked to short-term cancer risk Data don ’t support HRT for chronic disease prevention (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 29, 2019 Category: UK Health Source Type: news
valsartan/hydrochlorothiazide (Diovan HCT)
Title: valsartan/hydrochlorothiazide (Diovan HCT)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 19, 2019 Category: Cardiology Source Type: news
